Eribulin -- Benefit Assessment According to §35a Social Code Book V [Internet].

The aim of the present report was to assess the added benefit of eribulin for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapies should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.

http://ift.tt/2ssv7Lr